Download Free Antimicrobial Chemotherapy Bayer Edition Book in PDF and EPUB Free Download. You can read online Antimicrobial Chemotherapy Bayer Edition and write the review.

Antimicrobial agents are essential for the treatment of life-threatening infections and for managing the burden of minor infections in the community. In addition, they play a key role in organ and bone marrow transplantation, cancer chemotherapy, artificial joint and heart valve surgery. Unlike other classes of medicines, they are vulnerable to resistance from mutations in target microorganisms, and their adverse effects may extend to other patients (increased risk of cross-infection). As a consequence, there is a constant requirement for new agents, as well as practices that ensure the continued effective prescribing of licensed agents. Public awareness and concerns about drug resistant organisms has led to widespread publicity and political action in the UK, Europe and worldwide. The control of drug resistance and the implementation of good prescribing practice are now legal requirements in the UK as a result of the UK Health Act (2008). These fundamental changes underscore the need for a thorough understanding of the advantages and risks associated with specific antibiotic choices. This sixth edition of Antimicrobial Chemotherapy continues to be a valuable resource for undergraduates and graduates requiring a thorough grounding in the scientific basis and clinical application of these drugs. This new edition is updated to include the most recently licensed agents, notably in the treatment of viral infections including HIV/AIDS, and contains new guidance on prescribing practice and infection control practices that limit the development and spread of resistant organisms.
Antimicrobial agents are essential for the treatment of life-threatening infections and for managing the burden of minor infections in the community. In addition, they play a key role in organ and bone marrow transplantation, cancer chemotherapy, artificial joint and heart valve surgery. Unlike other classes of medicines, they are vulnerable to resistance from mutations in target microorganisms, and their adverse effects may extend to other patients (increased risk of cross-infection). As a consequence, there is a constant requirement for new agents, as well as practices that ensure the continued effective prescribing of licensed agents. The fully revised and updated seventh edition of Antimicrobial Chemotherapy is an essential guide to the principles of antimicrobial chemotherapy, the problem of resistance and its control through policies, antimicrobial stewardship and surveillance. The book provides an aid to informed, rational prescribing for common bacterial, fungal, parasitic and viral infections. Divided in five parts, the book cover issues specific to both the developed and developing world. Part 1 'General property of antimicrobial agents' discusses mechanisms of action and resistance to antibacterial, antifungal antiprotozoal, antiviral, and antiviral agents. Part 2 'Resistance to antimicrobial agents' provides guidance about the problem of resistance, mechanisms of acquired resistance and genetics of resistance. Part 3 'General principles of usage of antimicrobial agents' analyses the use of the laboratory, general principles of the treatment of infection, dosing in special groups (extremes of age, pregnancy, obesity), safe prescribing, prophylaxis and the role of policies in antimicrobial stewardship. Part 4 'Therapeutic use of antimicrobial agents' provides advice about the treatment of common infections which are described by anatomical. There are also chapters on the management of mycobacterial disease, viral infections, HIV/AIDS and parasitic infections. The final part of the book analyses the development and marketing of antimicrobial drugs. This seventh edition of Antimicrobial Chemotherapy continues to be a valuable resource for undergraduates and graduates requiring a thorough grounding in the scientific basis and clinical application of these drugs.
Instilling good prescribing habits in young doctors is essential for the benefit of patients and to preserve the value of the antibiotic revolution that altered medical practice in the second half of the twentieth century. These concerns underlie the approach taken in the new edition of this successful book. The text provides a comprehensive and up-to-date account of the principles of antimicrobial chemotherapy as an aid to informed, rational prescribing. Care is taken to address all aspects of antimicrobial drug use, including those specific to developed and developing countries of the world. The authors are international experts with a long standing interest in the role of education as a means of promoting an understanding of the benefits and limitations of antimicrobial chemotherapy in physicians, surgeons and other health care workers. The book offers a structured approach to the subject in four themed sections, each of several chapters. A historical introduction is followed by a section outlining the basic properties of antibacterial, antifungal, antiparasitic and antiviral (including antiretroviral) drugs.The next section explains the various facets of antimicrobial drug resistance - which threatens to undermine the continued efficacy of antimicrobial agents - and effective ways of countering the threat. Therapeutic use is covered in two sections: one introduces readers to the general principles that inform the rational prescribing of antimicrobial drugs; the second deals with practicalities of the use of antimicrobial agents in specific clinical conditions. The book ends with a description of the ways in which drugs are developed and marketed. There are extensive recommendations for further reading.
Implement the most current science and practice in antimicrobial research. Now, find the newest approaches for evaluating the activity, mechanisms of action, and bacterial resistance to antibiotics with this completely updated, landmark reference. Turn to this comprehensive reference for groundbreaking evidence on the molecular link between chemical disinfectants, sterilants, and antibiotics. On the latest methods for detecting antibacterial resistance genes in the clinical laboratory, and antivirogram use to select the most active antiviral components against your patient's HIV.
Biofilms in Infection and Disease Control: A Healthcare Handbook outlines the scientific evidence and rationale for the prevention of infection, the role biofilms play in infection control, and the issues concerning their resistance to antimicrobials. This book provides practical guidance for healthcare and infection control professionals, as well as students, for preventing and controlling infection. Biofilms are the most common mode of bacterial growth in nature. Highly resistant to antibiotics and antimicrobials, biofilms are the source of more than 65 percent of health care associated infections (HCAI), which, according to the WHO, affect 1.4 million people annually. Biofilms are involved in 80 percent of all microbial infections in the body, including those associated with medical devices such as catheters, endotracheal tubes, joint prostheses, and heart valves. Biofilms are also the principle causes of infections of the middle-ear, dental caries, gingivitis, prostatitis and cystic fibrosis. Importantly, biofilms also significantly delay wound healing and reduce antimicrobial efficiency in at-risk or infected skin wounds. - Provides specific procedures for controlling and preventing infection - Includes case studies of HCAI, and identifies appropriate treatments - Presents national government standards for infection prevention and control - Includes extensive references and links to websites for further information
One of a series of pocketbooks designed to provide easily assimilable information on common medical issues. The concise texts are enhanced by tables and diagrams summarizing the essential information. This volume deals with antimicrobial therapy.
Our ability to treat common bacterial infections with antibiotics goes back only 65 years. However, the authors of this report make it clear that sustaining a supply of effective and affordable antibiotics cannot be without changes to the incentives facing patients, physicians, hospitals, insurers, and pharmaceutical manufacturers. In fact, increasing resistance to these drugs is already exacting a terrible price. Every day in the United States, approximately 172 men, women, and children die from infections caused by antibiotic-resistant bacteria in hospitals alone. Beyond those deaths, antibiotic resistance is costing billions of dollars through prolonged hospital stays and the need for doctors to resort to ever more costly drugs to use as substitute treatments. Extending the Cure presents the problem of antibiotic resistance as a conflict between individual decision makers and their short-term interest and the interest of society as a whole, in both present and future: The effort that doctors make to please each patient by prescribing a drug when it might not be properly indicated, poor monitoring of discharged patients to ensure that they do not transmit drug-resistant pathogens to other persons, excesses in the marketing of new antibiotics, and the broad overuse of antibiotics all contribute to the development and spread of antibiotic-resistant bacteria. The book explores a range of policy options that would encourage patients, health care providers, and managed care organizations to serve as more responsible stewards of existing antibiotics as well as proposals that would give pharmaceutical firms greater incentives to develop new antibiotics and avoid overselling. If the problem continues unaddressed, antibiotic resistance has the potential to derail the health care system and return us to a world where people of all ages routinely die from simple infections. As a basis for future research and a spur to a critically important dialogue, Extending the Cure is a fundamental first step in addressing this public health crisis. The Extending the Cure project is funded in part by the Robert Wood Johnson Foundation through its Pioneer Portfolio.